Pediatric Bullous Pemphigoid Induced by Rivaroxaban: A Rare Case Report With Underlying Hereditary Hypercoagulability

Bullous pemphigoid (BP) is a rare autoimmune blistering disorder in pediatric patients. Although various medications have been implicated as potential triggers, hypersensitivity reactions associated with Rivaroxaban, a direct Factor Xa inhibitor, are rarely documented. We present a case of an 8-year-old male who developed widespread BP after 3 months of Rivaroxaban therapy. Histopathological and immunofluorescence findings confirmed the diagnosis. Discontinuation of Rivaroxaban and administration of systemic corticosteroids led to rapid clinical improvement. This case highlights Rivaroxaban-induced BP as a potential adverse reaction in children and underscores the need for awareness and prompt management of this rare but treatable condition.

Authors

Institutions

Publication Details

Journal
Pediatric and Developmental Pathology
Published
2025-12-18
DOI
https://doi.org/10.1177/10935266251404122
Citations
1
Primary Topic
Autoimmune Bullous Skin Diseases
Type
article
Field-Weighted Citation Impact
1.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pediatric Bullous Pemphigoid Induced by Rivaroxaban: A Rare Case Report With Underlying Hereditary Hypercoagulability

Van Thi Phan, Khôi Nguyen, Phi Duong Nguyễn, Tien Minh Nguyen et al.
1 citations
Pediatric and Developmental Pathology
Autoimmune Bullous Skin Diseases
1.47
article

Pediatric Bullous Pemphigoid Induced by Rivaroxaban: A Rare Case Report With Underlying Hereditary Hypercoagulability

Van Thi Phan, Khôi Nguyen, Phi Duong Nguyễn, Tien Minh Nguyen, Yen Hoang Phan, Diem Kieu Ly
article en
1 citations

Abstract

Bullous pemphigoid (BP) is a rare autoimmune blistering disorder in pediatric patients. Although various medications have been implicated as potential triggers, hypersensitivity reactions associated with Rivaroxaban, a direct Factor Xa inhibitor, are rarely documented. We present a case of an 8-year-old male who developed widespread BP after 3 months of Rivaroxaban therapy. Histopathological and immunofluorescence findings confirmed the diagnosis. Discontinuation of Rivaroxaban and administration of systemic corticosteroids led to rapid clinical improvement. This case highlights Rivaroxaban-induced BP as a potential adverse reaction in children and underscores the need for awareness and prompt management of this rare but treatable condition.

Pediatric and Developmental PathologyVol. 29(2)
Children's Hospital 2 (VN)
Openalex Percentile: Top 13%
Autoimmune Bullous Skin Diseases
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.